Nanomedicine in Cancer Therapy: What's New
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 2293
Special Issue Editor
Special Issue Information
Dear Colleagues,
I am honored to serve as a Guest Editor for this Special Issue of the Journal of Personalized Medicine entitled “Nanomedicine in Cancer Therapy: What's New”. Despite the significant progress achieved in the field of personalized cancer nanomedicine, the gap is still wide between preclinical research and clinical application. In addition, the potential of discovering several milestone pathways in the battle against cancer, including the inhibition of PD-1 and CTLA-4 by immune checkpoint inhibitors, CRIPR/Cas9 gene editing machinery, and novel tumor targeting approaches, is expected to be fully unleashed when these advanced therapeutics are combined with the clinical application of personalized nanomedicine. Several barriers that slow down the translation of nanomedicine-based research to the clinic need to be rationally discussed and investigated. Research in this field should not only focus on developing new and ‘smarter’ therapeutics, but also should extend to developing new ex vivo and in vivo cancer models, utilizing techniques such as 3D printing and bioprinting, and high-throughput screening, genotyping, and sequencing, to accurately represent patient-to-patient tumor heterogeneity and individual variability. Advances in nanomedicine application should not only be restricted to cancer therapy, but also extend to imaging and diagnostics. In this new Special Issue, we welcome review or research articles on novel trends in personalized cancer nanomedicine, especially when combined with new treatment venues with small molecules, macromolecules, and gene therapy, state-of-the-art technologies such as 3D bioprinting, and advanced theranostics.
Dr. Youssef W. Naguib
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomaterials
- nanomedicine
- enhanced permeation and retention
- theranostics
- controlled release
- combination therapy
- gene therapy
- CRISPR/Cas9
- immune checkpoint inhibitors
- 3D printing
- liposomes
- nanoparticles
- smart polymers
- tumor targeting
